EPCAM+ status, in combination with annexin V+ and ASGPR1+ fluorescence labeling, can be used as a noninvasive assessment of the presence and extent of CCA in patients with advanced liver diseases (24). This evidence concerns the gene ANXA5 and liver disorder.